Gastric Cancer
Positive Interim Results from Global Phase III MATTERHORN Study: Imfinzi plus FLOT Demonstrates Clinically Meaningful Improvement in Key Secondary Endpoint (ESMO 2023)
Anika Sharma
ESMO 2023: LBA73 The results of a MATTERHORN trial was presented in ESMO 2023. The trial tested the effect of ...
Merck’s Keytruda fails a study for early stomach cancer following metastatic disease victory
SG Tylor
Source – Merck Inhibiting immune checkpoints hasn’t been very effective against stomach cancer. Merck has now added another failure to ...
Keytruda Triumphs: Promising Progression-Free Survival in HER2-Positive Gastric Cancer
SG Tylor
Source: Merck Merck’s renowned cancer drug, Keytruda, may soon see an updated label for its effectiveness in treating HER2-positive stomach ...
